Falcone M, Paul M, Tiseo G, Yahav D, Prendki V, Friberg LE, et al. Considerations for the optimal management of antibiotic therapy in elderly patients. J Glob Antimicrob Resist. 2020;22:325–33.

Article  PubMed  Google Scholar 

Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: Basic principles and practical applications. Br J Clin Pharmacol. 2004;57:6–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rule AD, Gussak HM, Pond GR, Bergstralh EJ, Stegall MD, Cosio FG, et al. Measured and estimated gfr in healthy potential kidney donors. Am J Kidney Dis. 2004;43:112–9.

Article  PubMed  Google Scholar 

Herrera AP, Snipes SA, King DW, Torres-Vigil I, Goldberg DS, Weinberg AD. Disparate inclusion of older adults in clinical trials: Priorities and opportunities for policy and practice change. Am J Public Health. 2010;100:S105–12.

Article  PubMed  PubMed Central  Google Scholar 

Hilmer SN, Kirkpatrick CMJ. New horizons in the impact of frailty on pharmacokinetics: latest developments. Age Ageing. 2021;50:1054–63.

Article  PubMed  Google Scholar 

Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother. 1992;36:1532–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moon YS, Chung KC, Gill MA. Pharmacokinetics of meropenem in animals, healthy volunteers, and patients. Clin Infect Dis. 1997;24(Suppl 2):S249–55.

Article  CAS  PubMed  Google Scholar 

Leroy A, Fillastre JP, Borsa-Lebas F, Etienne I, Humbert G. Pharmacokinetics of meropenem (ici 194,660) and its metabolite (ici 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother. 1992;36:2794–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004;26:1187–98.

Article  CAS  PubMed  Google Scholar 

Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, et al. Substantial impact of altered pharmacokinetics in critically ill patients on the antibacterial effects of meropenem evaluated via the dynamic hollow-fiber infection model. Antimicrob Agents Chemother. 2017;61:e02642-e2716.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol. 2006;46:1171–8.

Article  CAS  PubMed  Google Scholar 

Usman M, Frey OR, Hempel G. Population pharmacokinetics of meropenem in elderly patients: Dosing simulations based on renal function. Eur J Clin Pharmacol. 2017;73:333–42.

Article  CAS  PubMed  Google Scholar 

Beal SL. Ways to fit a pk model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28:481–504.

Article  CAS  PubMed  Google Scholar 

Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: Intermittent bolus versus continuous administration? Monte carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother. 2009;64:142–50.

Article  CAS  PubMed  Google Scholar 

Krueger WA, Bulitta J, Kinzig-Schippers M, Landersdorfer C, Holzgrabe U, Naber KG, et al. Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother. 2005;49:1881–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ehmann L, Zoller M, Minichmayr IK, Scharf C, Huisinga W, Zander J, et al. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis. Int J Antimicrob Agents. 2019;54:309–17.

Article  CAS  PubMed  Google Scholar 

Lodise TP, Nau R, Kinzig M, Drusano GL, Jones RN, Sörgel F. Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: Results of population pharmacokinetic modelling and monte carlo simulation. J Antimicrob Chemother. 2007;60:1038–44.

Article  CAS  PubMed  Google Scholar 

Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet. 2005;44:539–49.

Article  CAS  PubMed  Google Scholar 

Ramon-Lopez A, Allen JM, Thomson AH, Dheansa BS, James SE, Hanlon GW, et al. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with monte carlo simulations. J Antimicrob Chemother. 2015;70:882–90.

Article  CAS  PubMed  Google Scholar 

Dhaese SAM, Farkas A, Colin P, Lipman J, Stove V, Verstraete AG, et al. Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. J Antimicrob Chemother. 2019;74:432–41.

Article  CAS  PubMed  Google Scholar 

Jaruratanasirikul S, Thengyai S, Wongpoowarak W, Wattanavijitkul T, Tangkitwanitjaroen K, Sukarnjanaset W, et al. Population pharmacokinetics and monte carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units. Antimicrob Agents Chemother. 2015;59:2995–3001.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim YK, Lee DH, Jeon J, Jang HJ, Kim HK, Jin K, et al. Population pharmacokinetic analysis of meropenem after intravenous infusion in korean patients with acute infections. Clin Ther. 2018;40:1384–95.

Article  CAS  PubMed  Google Scholar 

Muro T, Sasaki T, Hosaka N, Umeda Y, Takemoto S, Yamamoto H, et al. Population pharmacokinetic analysis of meropenem in japanese adult patients. J Clin Pharm Ther. 2011;36:230–6.

Article  CAS  PubMed  Google Scholar 

Jamsen KM, Patel K, Nieforth K, Kirkpatrick CMJ. A regression approach to visual predictive checks for population pharmacometric models. CPT Pharmacomet Syst Pharmacol. 2018;7:678–86.

Article  CAS  Google Scholar 

Gastonguay M. Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: A review of methodology and 42 case studies. In: Annual Meeting of the Population Approach Group Europe. 2011. Athens, Greece.

Fang J, Landersdorfer CB, Cirincione B, Jusko WJ. Study reanalysis using a mechanism-based pharmacokinetic/pharmacodynamic model of pramlintide in subjects with type 1 diabetes. AAPS J. 2013;15:15–29.

Article  PubMed  Google Scholar 

Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development-part 2: Introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst Pharmacol. 2013;2: e38.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It’s not just for mice anymore. Clin Infect Dis. 2007;44:79–86.

Article  CAS  PubMed  Google Scholar 

Mouton JW, Dudley MN, Cars O, Derendorf H, Drusano GL. Standardization of pharmacokinetic/pharmacodynamic (pk/pd) terminology for anti-infective drugs: An update. J Antimicrob Chemother. 2005;55:601–7.

Article  CAS  PubMed  Google Scholar 

Craig WA (1998) Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26: 1–10

Drusano GL. Antimicrobial pharmacodynamics: Critical interactions of “bug and drug.” Nat Rev Microbiol. 2004;2:289–300.

Article  CAS  PubMed  Google Scholar